Related Experiment Videos
Taxol: a novel radiation sensitizer
R B Tishler1, P B Schiff, C R Geard
1Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University, New York, NY.
International Journal of Radiation Oncology, Biology, Physics
|January 1, 1992
Summary
Investigational antineoplastic agent taxol enhances radiation therapy by selectively targeting cancer cells in the G2 and M phases. This combination therapy shows significant potential for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Cell Biology
- Radiotherapy
Background:
- Taxol (paclitaxel) is an antineoplastic agent derived from yew trees.
- It functions as a microtubule stabilizing agent, arresting cells in G2 and M phases.
- G2 and M phases are known to be the most radiosensitive cell cycle stages.
Purpose of the Study:
- To investigate taxol's potential as a cell-cycle selective radiosensitizer.
- To evaluate the combined effects of taxol and ionizing radiation on astrocytoma cells.
Main Methods:
- Exposure of human grade 3 astrocytoma cells (G18) to taxol and ionizing radiation.
- Survival curve analysis to assess cell killing efficacy.
- Determination of sensitizer enhancement ratio (SER).
Main Results:
- A significant synergistic interaction was observed between taxol and ionizing radiation.
- Enhanced cell killing was dependent on taxol concentration and cell cycle phase distribution.
- A sensitizer enhancement ratio (SER) of approximately 1.8 was achieved with 10 nM taxol.
Conclusions:
- Taxol acts as an effective cell-cycle selective radiosensitizer.
- Combined taxol-radiation therapy demonstrates potential for treating radioresistant brain tumors.
- Optimized timing and concentration of taxol are crucial for combined modality protocols.